{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,20]],"date-time":"2024-03-20T01:02:23Z","timestamp":1710896543702},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,19]]},"DOI":"10.7759\/cureus.56487","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T19:22:05Z","timestamp":1710876125000},"source":"Crossref","is-referenced-by-count":0,"title":["Erythema Multiforme in an HIV+ Patient on Highly Active Antiretroviral Therapy After Starting Paxlovid (Nirmatrelvir-Ritonivir)"],"prefix":"10.7759","author":[{"given":"Alison D","family":"C\u00e1ceres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristy","family":"Bono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Kothari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2011.05348.x","article-title":"Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist","volume":"51","author":"Sokumbi O","year":"2012","unstructured":"Sokumbi O, Wetter DA. Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. Int J Dermatol. 2012, 51:889-902. 10.1111\/j.1365-4632.2011.05348.x","journal-title":"Int J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjoms.2007.07.202","article-title":"Oral mucosal diseases: erythema multiforme","volume":"46","author":"Scully C","year":"2008","unstructured":"Scully C, Bagan J. Oral mucosal diseases: erythema multiforme. Br J Oral Maxillofac Surg. 2008, 46:90-5. 10.1016\/j.bjoms.2007.07.202","journal-title":"Br J Oral Maxillofac Surg"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/0030-4220(80)90052-3","article-title":"Histopathologic spectrum of oral erythema multiforme","volume":"49","author":"Buchner A","year":"1980","unstructured":"Buchner A, Lozada F, Silverman Jr S. Histopathologic spectrum of oral erythema multiforme. Oral Surg Oral Med Oral Pathol. 1980, 49:221-228. 10.1016\/0030-4220(80)90052-3","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0714.1995.tb01122.x","article-title":"Characteristics of the oral lesions in patients with cutaneous recurrent erythema multiforme","volume":"24","author":"Farthing PM","year":"1995","unstructured":"Farthing PM, Maragou P, Coates M, Tatnall F, Leigh IM, Williams DM. Characteristics of the oral lesions in patients with cutaneous recurrent erythema multiforme. J Oral Pathol Med. 1995, 24:9-13. 10.1111\/j.1600-0714.1995.tb01122.x","journal-title":"J Oral Pathol Med"},{"key":"ref5","article-title":"Mechanism and clinical research progress of nirmatrelvir tablets\/ritonavir tablets: a new therapeutic agent for COVID-19","volume":"57","author":"Zhang JW","year":"2022","unstructured":"Zhang JW, Hu X, Zhao ZN, Jin PF. Mechanism and clinical research progress of nirmatrelvir tablets\/ritonavir tablets: a new therapeutic agent for COVID-19. Chin Pharm J. 2022, 57:845-850.","journal-title":"Chin Pharm J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2646","article-title":"Recommendations for the management of drug-drug interactions between the COVID\u201019 antiviral nirmatrelvir\/ritonavir (Paxlovid) and comedications","volume":"112","author":"Marzolini C","year":"2022","unstructured":"Marzolini C, Kuritzkes DR, Marra F, et al.. Recommendations for the management of drug-drug interactions between the COVID\u201019 antiviral nirmatrelvir\/ritonavir (Paxlovid) and comedications. Clin Pharmacol Ther. 2022, 112:1191-200. 10.1002\/cpt.2646","journal-title":"Clin Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28441","article-title":"Efficacy and safety of nirmatrelvir\/ritonavir (Paxlovid) for COVID-19: a rapid review and meta-analysis","volume":"95","author":"Amani B","year":"2023","unstructured":"Amani B, Amani B. Efficacy and safety of nirmatrelvir\/ritonavir (Paxlovid) for COVID-19: a rapid review and meta-analysis. J Med Virol. 2023, 95:e28441. 10.1002\/jmv.28441","journal-title":"J Med Virol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/ced.15281","article-title":"Cutaneous adverse reactions to the new oral antiviral drugs against SARS-CoV-2","volume":"47","author":"Pupo Correia M","year":"2022","unstructured":"Pupo Correia M, Fernandes S, Filipe P. Cutaneous adverse reactions to the new oral antiviral drugs against SARS-CoV-2. Clin Exp Dermatol. 2022, 47:1738-40. 10.1111\/ced.15281","journal-title":"Clin Exp Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0008-2023","article-title":"Post nirmatrelvir\/ritonavir erythema multiforme in a patient with coronavirus disease infection","volume":"56","author":"Tavares-J\u00fanior JW","year":"2023","unstructured":"Tavares-J\u00fanior JW, Pompeu Filho JC, Galv\u00e3o LE. Post nirmatrelvir\/ritonavir erythema multiforme in a patient with coronavirus disease infection. Rev Soc Bras Med Trop. 2023, 56:e0008. 10.1590\/0037-8682-0008-2023","journal-title":"Rev Soc Bras Med Trop"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao B","year":"2020","unstructured":"Cao B, Wang Y, Wen D, et al.. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020, 382:1787-99. 10.1056\/NEJMoa2001282","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000417","article-title":"Hydroxychloroquine-induced erythema multiforme","volume":"23","author":"Abou Assalie N","year":"2017","unstructured":"Abou Assalie N, Durcan R, Durcan L, Petri MA. Hydroxychloroquine-induced erythema multiforme. J Clin Rheumatol. 2017, 23:127-8. 10.1097\/RHU.0000000000000417","journal-title":"J Clin Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13899","article-title":"A case of erythema multiforme major in a patient with COVID 19: the role of corticosteroid treatment","volume":"33","author":"Demirba\u015f A","year":"2020","unstructured":"Demirba\u015f A, Elmas \u00d6F, Atasoy M, T\u00fcrsen \u00dc, Lotti T. A case of erythema multiforme major in a patient with COVID 19: the role of corticosteroid treatment. Dermatol Ther. 2020, 33:e13899. 10.1111\/dth.13899","journal-title":"Dermatol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000515449","article-title":"Multisystem inflammatory syndrome in children associated with COVID- 19: a review with an emphasis on mucocutaneous and kawasaki disease-like findings","volume":"238","author":"Marzano AV","year":"2022","unstructured":"Marzano AV, Cassano N, Moltrasio C, Verdoni L, Genovese G, Vena GA. Multisystem inflammatory syndrome in children associated with COVID- 19: a review with an emphasis on mucocutaneous and kawasaki disease-like findings. Dermatology. 2022, 238:35-43. 10.1159\/000515449","journal-title":"Dermatology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.01.061","article-title":"Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors","volume":"63","author":"Introcaso CE","year":"2010","unstructured":"Introcaso CE, Hines JM, Kovarik CL. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors. J Am Acad Dermatol. 2010, 63:549-61; quiz 561-2. 10.1016\/j.jaad.2010.01.061","journal-title":"J Am Acad Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s0213-005x(08)76553-4","article-title":"Interacciones medicamentosas de darunavir [Pharmacological interactions with darunavir]","volume":"26","author":"Molt\u00f3 J","year":"2008","unstructured":"Molt\u00f3 J, Valle M, Clotet B. Interacciones medicamentosas de darunavir [Pharmacological interactions with darunavir]. Enferm Infecc Microbiol Clin. 2008, 26:43-50. 10.1016\/s0213-005x(08)76553-4","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1021\/ml1000257","article-title":"Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer","volume":"1","author":"Xu L","year":"2010","unstructured":"Xu L, Liu H, Murray BP, et al.. Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med Chem Lett. 2010, 1:209-13. 10.1021\/ml1000257","journal-title":"ACS Med Chem Lett"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0093-2","article-title":"Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir","volume":"52","author":"Cottrell ML","year":"2013","unstructured":"Cottrell ML, Hadzic T, Kashuba AD. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 2013, 52:981-94. 10.1007\/s40262-013-0093-2","journal-title":"Clin Pharmacokinet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18063","article-title":"Erythema multiforme in COVID-19 patients and following COVID-19 vaccination: manifestations, associations and outcomes","volume":"36","author":"Etaee F","year":"2022","unstructured":"Etaee F, Eftekharian M, Naguib T, Daveluy S. Erythema multiforme in COVID-19 patients and following COVID-19 vaccination: manifestations, associations and outcomes. J Eur Acad Dermatol Venereol. 2022, 36:e524-30. 10.1111\/jdv.18063","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14281","article-title":"Erythema multiforme-like eruption in patients with COVID-19 infection: clinical and histological findings","volume":"45","author":"Jimenez-Cauhe J","year":"2020","unstructured":"Jimenez-Cauhe J, Ortega-Quijano D, Carretero-Barrio I, Suarez-Valle A, Saceda-Corralo D, Moreno-Garcia Del Real C, Fernandez-Nieto D. Erythema multiforme-like eruption in patients with COVID-19 infection: clinical and histological findings. Clin Exp Dermatol. 2020, 45:892-5. 10.1111\/ced.14281","journal-title":"Clin Exp Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1159\/000496389","article-title":"An update on adverse cutaneous drug reactions in HIV\/AIDS","volume":"6","author":"Hoosen K","year":"2019","unstructured":"Hoosen K, Mosam A, Dlova NC, Grayson W. An update on adverse cutaneous drug reactions in HIV\/AIDS. Dermatopathology (Basel). 2019, 6:111-25. 10.1159\/000496389","journal-title":"Dermatopathology (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/192257-erythema-multiforme-in-an-hiv-patient-on-highly-active-antiretroviral-therapy-after-starting-paxlovid-nirmatrelvir-ritonivir","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T19:22:09Z","timestamp":1710876129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/192257-erythema-multiforme-in-an-hiv-patient-on-highly-active-antiretroviral-therapy-after-starting-paxlovid-nirmatrelvir-ritonivir"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.56487","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,19]]}}}